Apogee Therapeutics, Inc. (APGE)
APGE moved a median of +0.15% 30 minutes after news, and +0.15% by the close. How APGE actually reacts to news — the realized, point-in-time move the market made, measured across 343 labeled events over the last three years with zero look-ahead.
APGE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.06% | 57% | 320 |
| 30-min | +0.15% | 63% | 321 |
| 60-min | +0.19% | 63% | 321 |
| to close | +0.15% | 54% | 318 |
| Middle 50% of APGE reactions | -0.45% to +1.38% |
|---|---|
| Median reaction (30-min) | +0.15% |
| Measured reactions | 343 |
Half of all Apogee Therapeutics, Inc. news events land between -0.45% and +1.38% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How APGE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 34 | +0.04% | 77% | -0.06% |
| Coverage initiations | 37 | -0.90% | 24% | -2.58% |
| Rating reiterations | 61 | -0.09% | 44% | -0.80% |
| Price-target raises | 16 | -0.85% | 38% | -1.07% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how APGE ranks against every other measured name →
That’s how APGE usually reacts — get an email when it moves on news →Email me when APGE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to APGE's baseline. Nothing else.
Recent APGE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Apogee Therapeutics, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form 8-K Apogee Therapeutics, For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POSASR Apogee Therapeutics, | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Apogee Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Apogee Therapeutics, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | -0.08% | |
| Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | Press release | GlobeNewswire | +0.01% | — | |
| Form 10-Q Apogee Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.01% | — | |
| Form 8-K Apogee Therapeutics, For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | — | |
| Form DEFA14A Apogee Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.00% | +0.12% | |
| Form DEFA14A Apogee Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.02% | -0.04% | |
| Are DSGR, AVB, SLP, APGE Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.02% | -0.01% | |
| Form DEFM14A Apogee Therapeutics, | SEC filing · Form DEFM14A | SEC EDGAR | -0.10% | -0.03% | |
| Form PREM14A Apogee Therapeutics, For: Jul 02 | SEC filing · Form PREM14A | SEC EDGAR | -0.01% | +0.25% | |
| Form DEFA14A Apogee Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.02% | -0.07% | |
| Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | -0.01% | +0.01% | |
| APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | +0.13% | +0.00% | |
| Are ACA, CZR, APGE Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.01% | +0.23% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG) | Press release | GlobeNewswire | -0.02% | -0.06% | |
| Form 8-K Apogee Therapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | +0.00% | |
| Form 8-K Apogee Therapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | +0.00% | |
| Form DEFA14A Apogee Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.13% | +0.00% | |
| Form 8-K Apogee Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -1.34% | -3.87% | |
| Apogee Therapeutics to Participate in Upcoming June Conferences | Press release | GlobeNewswire | -0.33% | +5.01% | |
| Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart | Press release | GlobeNewswire | +1.59% | -0.95% | |
| Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis | Press release | GlobeNewswire | +1.59% | -0.95% | |
| Form 8-K Apogee Therapeutics, For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +1.59% | -0.95% | |
| Form 8-K Apogee Therapeutics, For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +1.59% | -0.95% | |
| Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026 | Press release | GlobeNewswire | +1.59% | -0.95% | |
| Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.01% | +0.73% | |
| Form 10-Q Apogee Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.01% | +0.73% | |
| Form 8-K Apogee Therapeutics, For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | +0.73% | |
| Form 8-K Apogee Therapeutics, For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | +0.39% | +1.24% | |
| Form ARS Apogee Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.39% | +1.24% | |
| Form DEF 14A Apogee Therapeutics, For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | +0.39% | +1.24% | |
| Form DEFA14A Apogee Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.39% | +1.24% | |
| Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million | Press release | GlobeNewswire | +0.53% | +0.17% | |
| Form 8-K Apogee Therapeutics, For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +1.19% | +1.66% | |
| Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering | Press release | GlobeNewswire | +4.87% | +5.28% | |
| Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis | Press release | GlobeNewswire | +2.36% | +2.91% | |
| Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering | Press release | GlobeNewswire | -2.08% | -8.15% | |
| Form 8-K Apogee Therapeutics, For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +2.36% | +2.91% | |
| Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 | Press release | GlobeNewswire | +2.36% | +2.91% | |
| Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results | Press release | GlobeNewswire | +0.57% | +4.44% | |
| Form 10-K Apogee Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.57% | +4.44% | |
| Form 8-K Apogee Therapeutics, For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +0.57% | +4.44% | |
| Form S-8 Apogee Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.57% | +4.44% | |
| Apogee Therapeutics to Participate in Upcoming March Conferences | Press release | GlobeNewswire | -0.58% | +1.29% | |
| Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +1.57% | -4.09% | |
| Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook | Press release | GlobeNewswire | +0.09% | +4.33% | |
| Form 8-K Apogee Therapeutics, For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | +4.33% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the APGE section they belong to.
Where else APGE is measured.
APGE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Apogee Therapeutics, Inc.'s median reaction calculated?
Every labeled APGE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 343 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 63% of APGE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does APGE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.